• Nocion Chronic Cough Study (PI: Amber Pepper)

  Study population: Adults with refractory or unexplained chronic cough for ≥ 12 months
  Drug: Taplucainium Powder (inhaler)
  Mechanism: charged sodium channel blocker, selectively blocks airway nociceptors
  Contact: Renee Smith; 813-631-4024 ext. 207; catherinesmith@usf.edu

• LEO Atopic Dermatitis Study (PI: Thomas Casale)
  

  Study population: Children (2 - 12 years) with moderate-to-severe AD on topical steroids
  Drug: tralokinumab (subQ injection)
  Mechanism:  anti-IL-13 monoclonal antibody
  Contact: Genie Alas; 813-631-4024 ext 200; eugenia4@usf.edu

• Blueprint CSU Study (PI: Thomas Casale)

  Study population: Adults with chronic spontaneous urticaria (can be omalizumab refractory)
  Drug: BLU-808, a small molekule wild type KIT inhibitor (oral)
  Mechanism: wild type KIT inhibitor; Prevents mast cell degranulation
  Contact: Renee Smith; 813-631-4024 ext. 207; catherinesmith@usf.edu

• Novartis RECLAIM CSU Study (PI: Amber Pepper)

  Study population: Adults with CSU (some can have failed omalizumab)
  Drug: remibrutinib vs dupilumab (NO placebo group)
  Mechanism: BTK inhibitor (oral) vs dupilumab (subQ)
  Contact: Renee Smith; 813-631-4024 ext. 207; catherinesmith@usf.edu

• DBV COMFORT peanut patch (PI: Amber Pepper)

  Study population: Toddlers (ages 1-3) with peanut allergy (DBPCFC required)
  Drug: Peanut patch
  Mechanism: epicutaneous immunotherapy (EPIT) for peanut desensitization
  Contact: Renee Smith; 813-631-4024 ext. 207; catherinesmith@usf.edu

Enrollment starting soon

• RAPT Food Allergy Study (PI: Thomas Casale)

  Study population: Ages 12-56 who are allergic to 1 or more of the following: peanut, milk, egg, cashew, walnut
  Drug: ozureprubart (SubQ injection, dosed every 8-12 weeks)
  Mechanism: Extended half-life anti-IgE monoclonal antibody (“biobetter” omalizumab) – can do between 1-3 challenge foods, depending on patient preference
  Contact: Renee Smith; 813-631-4024 ext. 207; catherinesmith@usf.edu

• Astria HAE Study (PI: Richard Lockey)

  Study population: Adults and adolescents (ages 12+) with HAE
  Drug: Navenibart (subQ injection)
  Mechanism: monoclonal antibody inhibiting plasma kallikrein (longer-acting, dosing every 3-6 months)
  Contact: Renee Smith; 813-631-4024 ext. 207; catherinesmith@usf.edu

• Eli Lilly CRSwNP Study (PI: Seong Cho)

  Study population: Adults and adolescents with CRS with nasal polyps despite intranasal steroid use
  Drug: Lebrikizumab (subQ injection)
  Mechanism: anti-IL-13 monoclonal antibody
  Contact: Genie Alas; 813-631-4024 ext 200; eugenia4@usf.edu

• Sanofi EFC18419 CRSwNP Study (PI: Seong Cho)
  

  Study population: Adults with CRS with nasal polyps
  Drug: itepekimab (subQ injection)
  Mechanism: anti-IL-33 monoclonal antibody
  Contact: Genie Alas; 813-631-4024 ext 200; eugenia4@usf.edu